Skip to main content
logo
NeoRich BioPharma Tech Co., Limited (NRBP)
OTCMKTS · Delayed Price · Currency is USD
1.170
+0.800 (216.13%)
At close: Oct 6, 2026

NeoRich BioPharma Tech Income Statement

Millions USD. Fiscal year is Oct - Sep.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Dec '24 Sep '24 Sep '23 Sep '22 Sep '21 Sep '20
Revenue
000---
Revenue Growth
-29.10%13.74%----
Cost of Revenue
000---
Gross Profit
000---
Selling, General & Admin
0.240.250.471.070.750.49
Operating Expenses
0.240.250.471.070.750.49
Operating Income
-0.23-0.25-0.47-1.07-0.75-0.49
Interest Expense
-0.03-0.03-0.12-0.05-0.77-0.67
Currency Exchange Gain (Loss)
-0.03-00-0.030.01-0
Other Non Operating Income (Expenses)
0.07-0.7300.22-3.26-1.15
EBT Excluding Unusual Items
-0.23-1.01-0.59-0.93-4.77-2.31
Asset Writedown
------0.43
Other Unusual Items
-00.020.060.240.26
Pretax Income
-0.23-1-0.57-0.88-4.53-2.48
Earnings From Continuing Operations
-0.23-1-0.57-0.88-4.53-2.48
Net Income to Company
-0.23-1-0.57-0.88-4.53-2.48
Minority Interest in Earnings
000000.04
Net Income
-0.23-1-0.57-0.88-4.53-2.44
Net Income to Common
-0.23-1-0.57-0.88-4.53-2.44
Net Income Growth
------
Shares Outstanding (Basic)
000000
Shares Outstanding (Diluted)
000000
Shares Change
28.47%41.33%15.55%37.46%257.86%10.81%
EPS (Basic)
-0.68-3.05-2.44-4.34-30.86-59.41
EPS (Diluted)
-0.68-3.05-2.44-4.34-30.86-59.41
EPS Growth
------

Additional Metrics

Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Dec '24 Sep '24 Sep '23 Sep '22 Sep '21 Sep '20
Free Cash Flow
-0.03-0.03-0.07-0.43-0.21-0.61
Free Cash Flow Per Share
-0.10-0.09-0.32-2.11-1.40-14.81
Gross Margin
44.90%50.91%31.02%---
Operating Margin
-7807.69%-7278.06%-15810.84%---
Profit Margin
-7536.88%-29454.52%-18971.82%---
Free Cash Flow Margin
-1098.63%-823.64%-2462.91%---
EBIT
-0.23-0.25-0.47-1.07-0.75-0.49
Advertising Expenses
-0.010.04---